• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development

    How Can Automation Optimize Immunohistochemistry?
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Biosynth Carbosynth

    Vector Partners Limited

    IDT Biologika

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Biosynth Carbosynth

    Vector Partners Limited

    IDT Biologika

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CDMOs On The Rise

    Tracking growth and strategies in the CDMO business

    CDMOs On The Rise
    Related CONTENT
    • Corden Pharma
    • Grand River Aseptic Manufacturing
    • Asymchem
    • Avara Pharmaceutical Services
    • Mogene
    Michel Le Bars, Managing Partner, Kurmann Partners AGe01.25.19
    The pharma outsourcing market promises robust and attractive growth although with differences in growth rate and profitability by market segment. Are there differentiating strategies to capture the growth of the pharma contract manufacturing market? How can pharmaceutical companies take advantage of the on-going consolidation?

    “The whole is greater than the sum of its parts”
    Aristotle’s quote finds some resonance when it comes to assessing the global market for pharmaceutical outsourcing. Adding the sales estimates of the contract development manufacturing organizations (CDMOs) and contract research organizations (CROs) results in a market size greater than $120 billion, but it is likely far from reflecting its full potential. For 2017, the contract manufacturing market alone is estimated at about $70-75 billion including clinical supplies, active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs).

    The share of the API contract manufacturing (merchant) market is roughly $50 billion, which is still less than 40% of the global synthetic API market, comprising advanced intermediates and chemically synthesized APIs. Indeed, captive use, i.e. pharmaceutical companies’ production for their own needs, still accounts for a larger proportion of total API supply. At a time when larger pharmaceutical companies are focusing on reducing their operational expenses and prioritizing capital investments on their most innovative products, this in-house capacity represents in itself a large reservoir adding to the growth potential of the CDMO industry.

    Additional factors providing a solid foundation for growth include worldwide improvement in access to medicines, in particular for generic drugs. Innovative and targeted therapies constitute another growth driver and not only for larger molecules. For instance, the small molecule API market benefits from favorable dynamics fueled by strong drug approval rates by the FDA—46 novel drugs including 34 small molecules in 2017—an increasing number of molecules in clinical phases and increasing outsourcing by the pharmaceutical companies.

    These factors contribute to promising growth of 6-7% per year across all geographies resulting in outsourced manufacturing valued at above $100 billion by 2022.

    Capturing the value in CDMO services
    The main three segments in the CDMO value chain present different growth patterns; for companies such as Patheon, Lonza or AMRI, the revenue growth rates range:

    • single digit for conventional FDFs (e.g. tablets); as opposed to:
    • between 10-20% for drug development services; or
    • between 15-25% for more complex FDFs (e.g. injectables) and API production.

    However, any assessment of the profitability requires a finer sub-segmentation. For instance, the API market attractiveness is a result of the increasing global API demand and the limited number of contract manufacturing organizations (CMOs) with differentiated capabilities, capacity and scale. On the one hand, large volume businesses—typically commodity APIs mainly exported from Asia—return lower margins (3-4%). On the other hand, custom synthesis is a much more profitable business based on the exclusive know-how of the supplier, often integrated with contract research and drug discovery activity for innovative APIs. Many European API manufacturers enjoy 20-25% EBITDA margin. High-potency APIs is another very valuable segment but also very demanding, process-wise, due to stringent containment requirements.

    Similarly, in the FDF segment, the CDMOs that have followed a value-driven strategy—versus a volume approach—by adding services or investing in more complex technologies deliver higher returns (e.g. Catalent).
    How can CDMOs achieve differentiation?

    The last 12 months have seen a series of capital investment and acquisition announcements aiming at realizing differentiating strategies, such as gaining scale, establishing a specialist position or vertically integrating to offer a one-stop-shop.

    Gaining scale
    Successfully gaining scale requires outstanding execution. Lean initiatives throughout the organization are needed to achieve operational excellence, reduced complexity and competitive costs per unit. More conventional technologies may be adequate vehicles for growth as long as the entire organization shares this excellence mindset (e.g. commercial teams bring in relevant scalable volumes and manufacturing teams maximize capacity outputs with low waste levels).

    Another component of this strategy is geographic expansion, but under the condition of getting sufficient critical mass. We estimate the minimum revenue per FDF site should be at least $50 million in order to leverage economies of scale—and at $30 million for an API site. This seems to be the strategic path followed by Avara Pharmaceutical Services, a fairly recent entrant into the CDMO market, which has built its network over the last three years by acquiring businesses from Big Pharma such as UCB, Astra Zeneca and Pfizer. Its latest acquisition is the largest sterile manufacturing facility for injectable medicines in Canada from Sandoz as part of a continuing expansion of its global footprint.

    Establishing a “specialist” position
    Developing expertise in selected advanced technologies usually leads to higher profitability as illustrated by specialized API CMOs (e.g. steroids or hormones) which exhibit higher EBITDA margin, typically in the 20-25% range. 

    On the FDF CMO side, Recipharm’s Solids and Others segment delivers 15.2% EBITDA margin when, in comparison, its Sterile Liquids segment including vials and ampoules, lyophilizates and blow-fill-seal products delivers close to 20%. Its Sterile Liquid segment is built on technology-driven acquisitions such as Nitin Lifesciences, Corvette Pharmaceuticals, Mitim or Alcon’s Kaysersberg plant.

    The sterile manufacturing demand remains strong and capacity shortage is leading Pharma companies to expand their in-house capacities (e.g Pfizer, Aspen or J&J). It also motivates CDMOs (e.g Grand River Aseptic Manufacturing, Novasep or Fujifilm) to expand their facilities and to invest in high-speed, latest isolator manufacturing technology and fully integrated packaging lines.

    Is there a sweet spot? A significant proportion of new drugs in development are targeting more specialized medicines, with immuno-oncology being an area of intense activity. Hence, combining development capabilities, high potency API production and sterile liquid formulation dosages is certainly an attractive playground.

    Offering a one-stop-shop
    This model requires vertical integration and is limited to the major players and consolidators.

    The acquisition of Capsugel was a major milestone in Lonza Pharma & Biotech’s strategic plan to become a provider of one-stop-shop services and solutions for its customers. The takeover of Micro-Macinazione is complementing its micronization capabilities to meet the growing demand for improved bioavailability and efficacy of drug products.

    Similarly, Catalent’s $133 million deal for Juniper Pharmaceutical further supports its strategic goal to be the most comprehensive partner for pharmaceutical innovators adding high-end, fee-for-service development and clinical trials manufacturing to its offering.

    The one-stop-shop model seems clearly beneficial to smaller biotechs and virtual pharma companies with biologics needs. Big pharmaceutical companies, in which development and procurement teams usually follow different reporting lines, remain to be convinced.

    Pharma companies may take advantage of the players’ M&A appetite
    The last five years have seen the emergence of larger players through consolidation or acquisition of pharma sites: Aenova or Catalent have favored targeting CDMOs as illustrated by Catalent’s acquisition of Cook Pharmica. Delpharm, Famar, Corden, Patheon, or more recently, Avara, have been identified as the usual suspects when it comes to bidding for Pharma divestments. The M&A activity remains intense for FDFs capabilities as illustrated by Recipharm’s recent acquisition of Sanofi’s inhalation business. There have been fewer divestments in the API area, but a consolidation is also taking place in that segment driven by European-based companies backed by private equity groups: Spanish Suanfarma, Italian P&R Holding (including Olon and Fidia with sales above €750mn) or French Novacap (reaching sales of $1 billion since the acquisition of PCAS and PCI Synthesis).

    In addition, we observe an increasing interest for both facilities and products of credible Korean, Chinese and Indian CMOs or generic companies as well as other associations of western financial investors supported by operating vehicles, all pursuing a strategy to become integrated generic companies.

    As the larger pharma companies reshuffle their product portfolio to focus on selected therapeutic areas, they also prioritize in-house investments on their most innovative products, e.g. Novartis with its investment into a cell- and gene-therapy manufacturing unit at their site in Stein, Switzerland.

    The pharma companies can benefit by divesting manufacturing operations together with products before their patent expiry. This requires internal competencies to better manage product lifecycle, anticipate capacity planning and to engage early enough in a transaction process.

    Many larger pharma companies clearly state that acting as a CMO does not fit with their strategy and recognize the divestment decision is still a tough one. The valuation expectations need to account for many variables: the commercial long-term landscape, future CAPEX constraints, operational efficiency in comparison to best-in class and true market value of the assets. It also requires M&A advisory that not only masters the transaction process from carving-out to closing, but importantly understands the full span of the value chain and achievable synergies. 



     
    Michel Le Bars is Managing Partner at Kurmann Partners AG, an M&A advisory boutique based in Basel, Switzerland and specialized in the Pharma & Medtech industries. He was previously in charge of business development for EMEA at Merck & Co / MSD. He can be reached at www.kurmannpartners.com.
    Related Searches
    • pfizer
    • Development
    • discovery
    • liquids
    Suggested For You
    Corden Pharma Corden Pharma
    Grand River Aseptic Manufacturing Grand River Aseptic Manufacturing
    Asymchem Asymchem
    Avara Pharmaceutical Services Avara Pharmaceutical Services
    Mogene Mogene
    Zile Bonbons Zile Bonbons
    Recipharm Recipharm
    Vetio Animal Health Vetio Animal Health
    Digitization: Pharma 4.0 Digitization: Pharma 4.0
    Thousand Oaks Expands Bio CDMO Biz Thousand Oaks Expands Bio CDMO Biz
    3P Biopharmaceuticals Completes Facility Expansion 3P Biopharmaceuticals Completes Facility Expansion
    Injectables Go Deeper Injectables Go Deeper
     Dedicated to Excellence Dedicated to Excellence
    Getting to First-in-Human Clinical Trials Getting to First-in-Human Clinical Trials
    Micro-Sphere Micro-Sphere's MG2 Tekna Starts Production

    Related Content

    • APIs | Injectables
      Corden Pharma

      Corden Pharma

      ...
      Abby Thompson, Global Marketing Communications Manager 12.02.21

    • Clinical Trials
      Grand River Aseptic Manufacturing

      Grand River Aseptic Manufacturing

      ...
      Chelsea Keeton, Sr. Manager, Marketing and PR 11.22.21

    • Asymchem

      Asymchem

      ...
      Mandy Boyd, Asymchem 12.01.20


    • Avara Pharmaceutical Services

      Avara Pharmaceutical Services

      ...
      Jennifer R. Walters, Communications Lead 12.01.20

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Pylon Coatings Uses Polygiene Biomaster & Verimaster for Antimicrobial Surface Protection
      Sto Corp. Recognized with Multiple Honors at the EIFS Hero Awards
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Hanmi Fine Chemical Launches CDMO Business
      DFE Pharma Opens India CoE for Fast-Track Formulation Services
      Helsinn Establishes New R&D Hub in the U.S.
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Carlyle To Acquire HCP Packaging
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Sonoco Announces Transition of Chief Financial Officer
      Azelis Expands Presence in India
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Zeller+Gmelin named Berry Global’s 2021 Ink Supplier of the Year
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login